UnitedHealthcare and Humana are ending Medicare Advantage plans for nearly 1 million people

Medicare Advantage insurers are continuing to prioritize margins over growth in 2027 by reducing benefits, increasing cost-sharing, narrowing networks, and ending plans. Humana plans affecting about 600,000 members and UnitedHealthcare plans affecting about 390,000 members are ending; Clover Health’s maximum out-of-pocket cost rose by $1,144 for all members in Leerink’s sample. KFF analysis also found that 4 million standalone Part D enrollees who had $0 premiums last year no longer have that option, although eligible low-income subsidy recipients may still qualify.

Analysis

The market mechanism is a shift from enrollment-led growth to underwriting discipline, but lower benefits are not automatically higher earnings: savings depend on retaining members in leaner products without worsening risk mix or triggering costly churn. If healthier, price-sensitive members leave faster than high-need members, medical-cost pressure could persist despite higher cost-sharing and tighter networks. Narrower networks may also invite access complaints or regulatory scrutiny; monitor CMS actions and quality ratings rather than assuming benefit cuts flow cleanly to margins.

Near term, the enrollment period makes retention and plan switching the key catalysts. HUM faces execution risk around recapturing members from terminated plans; management’s stated intent is not evidence of successful retention. CLOV’s reported out-of-pocket increase creates a similar member-value test, although relative plan value—not year-over-year benefit change alone—will determine the outcome. Over 6–18 months, growth in C-SNPs could support differentiated care management, but the benefit depends on risk-adjusted economics and execution, not category growth alone.

The contrarian risk is that investors may treat pullbacks as an unambiguously positive margin reset. The upside case is real if leaner offerings retain profitable members and utilization normalizes; the downside is continued cost pressure alongside lost scale. CVS is a peer to diligence, not an assumed winner: the article provides no company-specific evidence on its 2027 offerings.

Key Decisions for Investors

• Keep HUM and CLOV underweight pending 2027 enrollment and retention evidence; avoid treating benefit reductions as confirmed earnings accretion. Reassess when company disclosures show recapture, membership mix, and medical-cost trends.
• For HUM, use plan-exit recapture as the near-term falsification test: stronger-than-expected retention into remaining plans would weaken the bearish thesis; material net membership losses or adverse mix would reinforce it.
• Track CNC and CVS filings for comparable benefit, network, and plan-exit decisions before taking a payer pair trade. The supplied evidence does not establish a clean long-side hedge or relative valuation case.
• Watch CMS quality/access actions and subsequent medical-cost guidance over the next 1–3 months; adverse developments could erase savings from tighter benefits, while stable costs and retained membership would support the margin-repair thesis.